Psychometric properties of the EORTC QLQ-C30 in Uganda.


Journal

Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626

Informations de publication

Date de publication:
23 Apr 2021
Historique:
received: 11 12 2020
accepted: 13 04 2021
entrez: 24 4 2021
pubmed: 25 4 2021
medline: 1 6 2021
Statut: epublish

Résumé

Self-reported measures play a crucial role in research, clinical practice and health assessment. Instruments used to assess self-reported health-related quality of life (HRQoL) need validation to ensure that they measure what they are intended to, detect true changes over time and differentiate between subjects. A generic instrument measuring HRQoL adapted for use among people living with cancer in Uganda is lacking; therefore, this study aimed to evaluate the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in patients with cancer in Uganda. Adult patients with various types of cancer (n = 385) cared for at the Uganda Cancer Institute answered the EORTC QLQ-C30 in Luganda or English language, the two most spoken languages in the country. The two language versions were evaluated with regard to data quality (floor and ceiling effects and missing responses), reliability (internal consistency) and validity (construct, known-group and criterion). Construct validity was examined through confirmatory factor analysis (CFA). Mean scores were compared between groups differing in disease stage to assess known-group validity. Criterion validity was examined according to associations between two QLQ-C30 subscales (Global quality of life and Physical function) and the Karnofsky Performance Scale (KPS). Floor and ceiling effects were observed for several scales in the Luganda and English versions. All EORTC scales with the exception of Cognitive function (Luganda α = 0.66, English α = 0.50) had acceptable Cronbach's alpha values (0.79-0.96). The CFA yielded good fit indices for both versions (RMSEA = 0.08, SRMR = 0.05 and CFI = 0.93). Known-group validity was demonstrated with statistically significant better HRQoL reported by patients with disease stages I-II compared to those in stages III-IV. Criterion validity was supported by positive correlations between KPS and the subscales Physical function (Luganda r = 0.75, English r = 0.76) and Global quality of life (Luganda r = 0.59, English r = 0.72). The Luganda and English versions of the EORTC QLQ-C30 appear to be valid and reliable measures and can be recommended for use in clinical research to assess HRQoL in adult Ugandans with cancer. However, the cognitive scale did not reach acceptable internal consistency and needs further evaluation.

Sections du résumé

BACKGROUND BACKGROUND
Self-reported measures play a crucial role in research, clinical practice and health assessment. Instruments used to assess self-reported health-related quality of life (HRQoL) need validation to ensure that they measure what they are intended to, detect true changes over time and differentiate between subjects. A generic instrument measuring HRQoL adapted for use among people living with cancer in Uganda is lacking; therefore, this study aimed to evaluate the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in patients with cancer in Uganda.
METHODS METHODS
Adult patients with various types of cancer (n = 385) cared for at the Uganda Cancer Institute answered the EORTC QLQ-C30 in Luganda or English language, the two most spoken languages in the country. The two language versions were evaluated with regard to data quality (floor and ceiling effects and missing responses), reliability (internal consistency) and validity (construct, known-group and criterion). Construct validity was examined through confirmatory factor analysis (CFA). Mean scores were compared between groups differing in disease stage to assess known-group validity. Criterion validity was examined according to associations between two QLQ-C30 subscales (Global quality of life and Physical function) and the Karnofsky Performance Scale (KPS).
RESULTS RESULTS
Floor and ceiling effects were observed for several scales in the Luganda and English versions. All EORTC scales with the exception of Cognitive function (Luganda α = 0.66, English α = 0.50) had acceptable Cronbach's alpha values (0.79-0.96). The CFA yielded good fit indices for both versions (RMSEA = 0.08, SRMR = 0.05 and CFI = 0.93). Known-group validity was demonstrated with statistically significant better HRQoL reported by patients with disease stages I-II compared to those in stages III-IV. Criterion validity was supported by positive correlations between KPS and the subscales Physical function (Luganda r = 0.75, English r = 0.76) and Global quality of life (Luganda r = 0.59, English r = 0.72).
CONCLUSION CONCLUSIONS
The Luganda and English versions of the EORTC QLQ-C30 appear to be valid and reliable measures and can be recommended for use in clinical research to assess HRQoL in adult Ugandans with cancer. However, the cognitive scale did not reach acceptable internal consistency and needs further evaluation.

Identifiants

pubmed: 33892718
doi: 10.1186/s12955-021-01769-x
pii: 10.1186/s12955-021-01769-x
pmc: PMC8066473
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

131

Subventions

Organisme : UCI-African Development Bank Training Scholarship
ID : 342/411/01

Références

Ann Oncol. 2013 Aug;24(8):2151-8
pubmed: 23567145
Eur J Cancer. 2007 Aug;43(12):1810-20
pubmed: 17689070
Cancer. 1984 May 1;53(9):2002-7
pubmed: 6704925
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Pain Symptom Manage. 2007 Dec;34(6):657-65
pubmed: 17618079
Lancet Oncol. 2013 Apr;14(4):e142-51
pubmed: 23561745
J Pain Symptom Manage. 2014 Mar;47(3):652-8
pubmed: 23910628
Health Qual Life Outcomes. 2019 Dec 12;17(1):182
pubmed: 31830992
East Afr Med J. 2007 Jan;84(1):24-30
pubmed: 17633581
Eur J Cancer. 2016 Oct;66:138-43
pubmed: 27573427
Eur J Cancer Care (Engl). 2016 Sep;25(5):832-8
pubmed: 26052872
BMC Med Inform Decis Mak. 2013 Jul 19;13:72
pubmed: 23870327
PLoS One. 2016 Jun 15;11(6):e0157359
pubmed: 27304066
Qual Life Res. 2005 Jun;14(5):1203-18; dicussion 1219-21, 1223-4
pubmed: 16047498
PLoS One. 2017 Oct 10;12(10):e0184360
pubmed: 29016607
Epidemiol Serv Saude. 2017 Jul-Sep;26(3):649-659
pubmed: 28977189
BMC Palliat Care. 2018 Jul 23;17(1):96
pubmed: 30037346
Int J Gynaecol Obstet. 2013 Aug;122(2):115-7
pubmed: 23759274
Psychometrika. 2009 Mar;74(1):107-120
pubmed: 20037639
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Health Qual Life Outcomes. 2012 Nov 02;10:133
pubmed: 23121718
Lancet Oncol. 2015 Aug;16(8):e385-93
pubmed: 26248846

Auteurs

Allen Naamala (A)

Department of Nursing, College of Health Sciences, Makerere University, Kampala, Uganda. namalallen@gmail.com.
Department of Medical Oncology, Uganda Cancer Institute, Kampala, Uganda. namalallen@gmail.com.

Lars E Eriksson (LE)

Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Medical Unit Infectious Diseases, Karolinska University Hospital, 141 86, Stockholm, Sweden.
School of Health Sciences, City, University London, London, EC1V 0HB, UK.

Jackson Orem (J)

Department of Medical Oncology, Uganda Cancer Institute, Kampala, Uganda.

Gorrette K Nalwadda (GK)

Department of Nursing, College of Health Sciences, Makerere University, Kampala, Uganda.

Zarina Nahar Kabir (ZN)

Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.

Lena Wettergren (L)

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH